Navigation Links
Researcher test first-in-class compound for neuroprotection, hope of stopping MS disease progression
Date:11/20/2013

A $500,000 drug development grant from the National Multiple Sclerosis Society (NMSS) was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead. She will test the effectiveness of a novel Karyopharm compound that can be orally administered and aimed at stopping the progressive phase of the disease. With the 14-month grant, Dr. Casaccia also hopes to gather information that will help design future clinical trials for MS treatments.

Karyopharm specializes in the synthesis of Selective Inhibitors of Nuclear Export, also known as SINE compounds. These compounds are thought to prevent the cause of irreversible damage to neurons, by blocking the early stages of neurodegeneration. Dr. Casaccia's laboratory first identified nuclear export as an important mechanism related to the initial events occurring in neurons and eventually leading to neurodegeneration. As inhibitors, these novel compounds target the nucleus in neurons, and block the accumulation of toxic substances in the axons. Axons are coated with myelin, and they can be damaged because myelin is destroyed or because they can be directly attacked by toxic factors that accumulate during the MS disease process. Neurodegenerative symptoms result from loss of myelin. Electrical signals are transmitted from the cell body of the neuron down an axon to other nerve cells, muscles, and other cells. Signal transmission slows down and progressive disability results from damage to the axons and loss of neurons, due to neurodegeneration.

Dr. Casaccia underscored the new strategy in MS drug development. "What's unique about this work is that SINE compounds target and prevent nuclear export, which is critically important for the neurodegenerative phase of the disease," she said. Preliminary experiments in Dr. Casaccia's laboratory have been encouraging. In mouse models, oral administration of the new compound to mice with paralysis of the tail and hindlimb, allowed them to walk again.

"The idea of rebuilding the nervous system and protecting it from ongoing MS damage was just a dream a few years ago," said Timothy Coetzee, Chief Advocacy, Services and Research Officer at the National MS Society. "Now, because of efforts by the research community as well as focused investments by the Society, we can see a future where people with MS will have treatments that could restore what's been lost."

In partnering with Karyopharm Therapeutics Inc., Dr. Casaccia will test these oral compounds in preclinical models and unravel their mechanism of action. The work would not be possible if the National MS Society did not invest $500,000 with Karyopharm through Fast Forward, as part of a comprehensive approach to MS research and treatment focusing on accelerating commercial development of promising research discoveries.,

"We look forward to collaborating with Dr. Casaccia, who has dedicated herself to advancing research in multiple sclerosis and other important diseases," said Karyopharm Founder, Chief Scientific Officer, and President of Research and Development, Sharon Shacham, PhD, MBA.

Fred Lublin, MD, Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center also applauded this research. "Developing novel approaches to treating the neurodegenerative component of MS is critically important for our efforts at halting this disease and then reversing the damage. Existing medications for MS only aim to reduce the number of relapses. They are not restorative to the nervous system."


'/>"/>

Contact: Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. NSU researchers receive $4.1 million grant from DOD to investigate Gulf War illness
2. Bedroom access to screen-based media may contribute to sleep problems in boys with autism, MU researchers find
3. Researchers Identify a New Genetic Risk Factor for Severe Psychiatric Illness
4. New Mobile Reporting Platform from OneWhitePixel Links Scientific Researchers With Field Reporters
5. Researchers find protein that regulates the burning of body fat
6. Water and Eye Health Researcher Offers Tips on Coping with Winter “Flu Eyes”
7. Johns Hopkins heart researchers develop formula to better calculate bad cholesterol in patients
8. U of M researchers find HIV protein may impact neurocognitive impairment in infected patients
9. Nanotech researchers 2-step method shows promise in fighting pancreatic cancer
10. Company co-founded by UH researcher wins Nanomedicine Award
11. Get Out and Play! Radio Flyer is Searching for Innovative New Ride-On Toys for Kids to Inspire Outdoor Play as Researchers Recommend Limiting Kids' Screen Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... ... ... Inc. magazine today revealed that RKC Products, a leader in the dietary supplement ... the nation’s fastest-growing private companies. With 200% revenue growth from 2015 to 2018, RKC ... list represents a unique look at the most successful companies within the American economy’s ...
(Date:8/14/2019)... ... 13, 2019 , ... In a recent Trivedi Effect workshop, Master Dahryn Trivedi ... systems. , “Doubt can obliterate your old beliefs,” said Master Dahryn. “Doubt helps you ... expand your understanding and your awareness. Trust that the Divine has put you here ...
(Date:8/12/2019)... ... August 12, 2019 , ... Cryotherapy has recently been the target of ... Raiders. However, the cause of Brown’s injury was not due to cryotherapy, but due ... Numerous NFL teams, such as the Dallas Cowboys, the Washington Redskins, the Denver Broncos ...
(Date:8/9/2019)... (PRWEB) , ... August 09, 2019 , ... The ... a class action complaint alleging that Mrs. Gooch's Natural Food Markets, Inc., failed to ... The Mrs. Gooch's Natural Food Markets, Inc., class action lawsuit, Case No. 19STCV26728, is ...
(Date:8/9/2019)... ... August 08, 2019 , ... ... on today’s issues affecting humanity at practical and spiritual levels. , Founder ... participants’ connection to the God of their understanding, as well as, to illuminate ...
Breaking Medicine News(10 mins):
(Date:8/10/2019)... ... August 10, 2019 , ... Founder Margie Barilla continues to ... obtain mental health screenings for early onset of depression, suicidal ideation, or behavioral ... to the community with free assessment reviews. At scheduled assessments students are given ...
(Date:8/9/2019)... ... August 09, 2019 , ... OCLI, ... at 360 Merrick Road, will be moving to a brand-new office in Oceanside, ... office offers additional features and technologies to enhance the patient experience in the ...
(Date:8/9/2019)... ... ... Working Against Gravity has published an infographic entitled “How to ... changes. , With this infographic, Working Against Gravity informs people on the ways to ... of your body. The infographic also provides helpful tips for staying on track once ...
Breaking Medicine Technology: